April 11, 2018 / 11:14 AM / 4 months ago

BRIEF-Mylan Partners With Fujifilm Kyowa Kirin Biologics

April 11 (Reuters) - Mylan NV:

* MYLAN PARTNERS WITH FUJIFILM KYOWA KIRIN BIOLOGICS TO COMMERCIALIZE BIOSIMILAR TO HUMIRA® (ADALIMUMAB)

* MYLAN NV - COMPANIES EXPECT TO RECEIVE A DECISION FROM EMA IN SECOND HALF OF 2018

* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS GRANTS MYLAN AN EXCLUSIVE LICENSE TO COMMERCIALIZE ADALIMUMAB BIOSIMILAR IN EUROPE

* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS IS ELIGIBLE TO RECEIVE A SUBSEQUENT COMMERCIALIZATION MILESTONE PAYMENT AND SALES ROYALTIES

* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS WILL RECEIVE AN UP-FRONT FEE UNDER DEAL

* MYLAN NV -CO, FUJIFILM KYOWA KIRIN BIOLOGICS CONTINUE TO NEGOTIATE FOR COMMERCIALIZING PRODUCT IN ADDITIONAL TERRITORIES

* MYLAN NV - UNDER AGREEMENT TERMS CO TO BE RESPONSIBLE FOR SALES ACTIVITY OF PRODUCT IN EUROPEAN COUNTRIES

* MYLAN NV - CO, FUJIFILM KYOWA KIRIN BIOLOGICS EXPECT TO RECEIVE DECISION FROM EMA REGARDING MAA FOR PROPOSED BIOSIMILAR TO HUMIRA IN H2 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below